Arkolith/Insider Trading/SYRS/Form 4

Haas Jason

Chief Financial OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Sep 12, 2024
Net Buying
Open-Market Buys
$161K
Open-Market Sells
$0
Net Open-Market Flow
$161K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 12, 2024Buy(P)45K$1.68$76K125K
Sep 11, 2024Buy(P)19K$1.58$30K79K
Sep 10, 2024Buy(P)35K$1.55$55K60K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-105995) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML